Protalix BioTherapeutics
PLX
37 hedge funds and large institutions have $58.4M invested in Protalix BioTherapeutics in 2015 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 9 closing their positions.
0.35% less ownership
Funds ownership: 3.43% → 3.08% (-0.35%)
1% less capital invested
Capital invested by funds: $59.3M → $58.4M (-$888K)
16% less funds holding
Funds holding: 44 → 37 (-7)
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
60% less call options, than puts
Call options by funds: $43K | Put options by funds: $108K
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$1.11M |
| 2 |
D.E. Shaw & Co
New York
|
+$184K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$102K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$44.1K |
| 5 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$3.92M |
| 2 |
RI
RTW Investments
New York
|
-$1.55M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$577K |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$392K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$300K |
PLX Hedge Fund Activity: Q1 2015 in Review
37 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2015, worth a combined $58.4M — down 1.5% from $59.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PLX and 2 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 7 added.
The largest buyer was Consonance Capital Management, adding an estimated $1.11M. The largest seller was Camber Capital Management, exiting entirely with an estimated $3.92M sold.
- 37 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2015, down from 44 in Q4 2014.
- Funds reported $58.4M of Protalix BioTherapeutics stock for Q1 2015, down 1.5% quarter-over-quarter.
- 2 funds opened new Protalix BioTherapeutics positions in Q1 2015 and 9 closed out, a net change of -7 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2015 was Consonance Capital Management, an estimated $1.11M added.
- The largest Protalix BioTherapeutics seller in Q1 2015 was Camber Capital Management, an estimated $3.92M sold.
Based on aggregated 13F filings for Q1 2015.